This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): RC-529
Description: RC-529 is a synthetic molecule that has been formulated as an adjuvant for vaccines. Adjuvants are added to vaccines to promote a stronger immune response to the vaccine in order to develop better immunity. RC-529 is capable of producing both mucosal and systemic immunity.
Deal Structure: Corixa entered into two license and two supply agreements in September 2001 with Wyeth, one of which amended and restated the companies prior license and supply agreements. Under the license agreements, Corixa granted Wyeth exclusive use of RC-529 adjuvant and MPL adjuvant for a specific autoimmune vaccine, co-exclusive use in certain infectious and autoimmune disease fields and nonexclusive use in one infectious disease field. Under the supply agreement, Corixa will provide Wyeth commercial quantities of RC-529 adjuvant and MPL adjuvant for use in any vaccines that Wyeth may develop under the license agreement. Under the agreements, Wyeth has agreed to pay Corixa an annual license fee until a threshold level of earned royalties is met, transfer payments for supplies of RC-529 adjuvant and MPL adjuvant and annual minimum and earned royalty payments when commercial sale of vaccines are made.
In February 2002, Corixa entered into a license and supply agreement with Berna Biotechs...See full deal structure in Biomedtracker
Partners: Johnson & Johnson GlaxoSmithKline plc
Pink Sheet Weekly Trademark Review May 19, 2015
Additional information available to subscribers only: